T. Rowe Price Associates’s BioXcel Therapeutics BTAI Stock Holding History

T. Rowe Price Associates’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,036	Closed	-$356K	–	2930
2022 Q4	$356K	Buy	1,036 +11	+1%	+$2.66K	﹤0.01%	2307
2022 Q3	$194K	Buy	1,025 +103	+11%	+$23.9K	﹤0.01%	2556
2022 Q2	$195K	Buy	922 +50	+6%	+$10.5K	﹤0.01%	2612
2022 Q1	$292K	Buy	872 +56	+7%	+$16.2K	﹤0.01%	2558
2021 Q4	$266K	Buy	816 +148	+22%	+$63.5K	﹤0.01%	2645
2021 Q3	$324K	Buy	668 +4	+0.6%	+$1.76K	﹤0.01%	2550
2021 Q2	$309K	Sell	664 -52	-7%	-$28.3K	﹤0.01%	2589
2021 Q1	$495K	Buy	716 +5	+0.7%	+$4.02K	﹤0.01%	2373
2020 Q4	$525K	Buy	+711	New	+$554K	﹤0.01%	2219

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Associates's BTAI Position: Q1 2023 in Review

T. Rowe Price Associates sold out of BioXcel Therapeutics (BTAI) in Q1 2023, closing a stake of 1,036 shares — an estimated $356K sold.

T. Rowe Price Associates first reported a position in BTAI in Q4 2020 and held it in 9 quarters. The position peaked at $525K in Q4 2020. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2023.

T. Rowe Price Associates reported no remaining BioXcel Therapeutics position as of Q1 2023 after selling out during the quarter.
T. Rowe Price Associates sold 1,036 BioXcel Therapeutics shares in Q1 2023, an estimated $356K.
T. Rowe Price Associates first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 9 quarters.
T. Rowe Price Associates's BioXcel Therapeutics position peaked at $525K in Q4 2020.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.